Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1837 - Phase II-trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell head and neck cancer: 5-year end results


09 Oct 2016


Poster display


Thomas Kuhnt


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


T. Kuhnt1, A. Schreiber2, A. Pirnasch3, M.G. Hautmann4, P. Hass5, F.P. Sieker6, R. Engenhart- Cabilic7, M. Richter8, K. Dellas9, J. Dunst9

Author affiliations

  • 1 Department Of Imaging And Radiation Medicine, University of Leipzig, 04103 - Leipzig/DE
  • 2 Private Praxis For Radiooncology, Krankenhaus Dresden-Friedrichstadt, Dresden/DE
  • 3 Department Of Radiation Oncology, Universitätsklinikum Rostock, Rostock/DE
  • 4 Department Of Radiotherapy, University of Regensburg, Regensburg/DE
  • 5 Department Of Radiotherapy, Otto-von Guericke-Universität, Magdeburg/DE
  • 6 Department Of Radiotherapy, Martin Luther Universität Halle-Wittenberg, Halle/Saale/DE
  • 7 Department Of Radiotherapy, Philipps University Marburg, Marburg/DE
  • 8 Coordination Center For Clinical Trials, Martin Luther Universität Halle-Wittenberg, Halle/Saale/DE
  • 9 North European Radiooncological Center, University Hospital UKSH, Kiel/DE


Abstract 1837


Cet is a potent inhibitor of the epidermal growth factor receptor and has shown activity in squamous cell carcinoma of the head and neck (SCCHN) enhancing both radiotherapy and chemotherapy. We conducted a single arm phase II-trial to investigate the feasibility, efficacy and safety of combination therapy with Cis, Cet and HART.


Patients (pts) with stage III or IV, M0 SCCHN were enrolled and treated with an initial dosage of Cet (400mg/m2), followed by weekly dosage of 250mg/m2 during HART, which started with a prescribed dosage of 2.0 Gy per day for three weeks followed by 1.4 Gy twice daily to a total dosage of 70.6 Gy to the gross tumor volume. Cis 40 mg/m2 was administered weekly (d1,8,15,22,29,36).


From November 2007 through November 2010, 74 pts were enrolled, 65 pts (83% men) with a median age of 56 years (range 37 to 69 years) were evaluable. The median Karnofsky status, 90%; range, 50% to 100%; oropharynx primary tumor, 49% of patients; T4a,b, 65%; N2/3, 95%; stage IVA/B disease, 92%. Of theses were 85% smokers or ex-smokers. In the OPC patients neither p16 and HPV16 status was investigated. Of these 60 pts (92%) > 90% RT dosage, 49 pts (75%) > 90% Cet dosage and 56 pts (82%) > 4 cycles Cis 40 mg/m2 were applied. Complete remission rate (CR) was observed in 23/65 (35%). The most common grade >3 toxicity were mucositis (58%) and dysphagia (52%), grade >2 Cet related toxicity included dermatitis acneiform (15%) within the radiotherapy portals. With a median follow-up of 27 months; range 0 to 69 months; the 2- and 5-year overall survival rates are 64% and 41%, the 2-and 5- year progression-free survival rate are 45% and 32%, and the 2-year and 5-locoregional control rates are 47% and 33%.


Combination therapy of SCCHN consisting of HART-Cis-Cet is an highly active regimen in this smoke - and alcohol-induced cancers. Further investigation is warranted to evaluate the efficacy of the trimodal approach in this very high risk patient Population.

Clinical trial identification

EudraCT 2005-000355-15

Legal entity responsible for the study



Merck Serono GmbH Darmstadt


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings